Vest Financial 13F: Cuts AbbVie (ABBV) Stake by $11M
Key Points
- Vest Financial cut its AbbVie Inc. position by 43,631 shares to finish the quarter with 224,688 shares worth about $58.8 million.
- AbbVie Inc. trades with a market capitalization near $499.5 billion and recently changed hands around $284.80 per share.
- Wall Street maintains a consensus buy rating on the drug manufacturer ahead of its upcoming October 30, 2026 earnings release.
Get AbbVie text alerts
We text you when insiders, Congress, analysts or big funds move on $ABBV.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated AbbVie Inc. alert may contain errors. Disclosures
Vest Financial trimmed its holdings in AbbVie Inc. (NYSE:ABBV) by 43,631 shares during the quarter, according to a Form 13F filing with the SEC on October 21, 2026. The adjustment lowered the fund's position by 16.2%, leaving it with 224,688 shares valued at approximately $58.8 million at the filing date.
ABBV
AbbVie Inc.
What Changed in Vest Financial's AbbVie Position
Vest Financial adjusted its exposure to the drug maker by dropping from 268,319 shares down to 224,688 shares. The reduction left the institutional investor with a smaller footprint in the North Chicago-based biopharmaceutical firm.
Other Institutional Activity in AbbVie
Other large investors also shifted their weight in the pharmaceutical company around the same period. Zwj Investment Counsel trimmed its stake by 6,901 shares to end with 334,519 shares valued at about $87.5 million. Trexquant Investment cut its holdings by 18,177 shares, leaving it with 77,280 shares worth roughly $19.5 million. Sumitomo Mitsui DS Asset Management Company reduced its position by 32,919 shares to hold 291,632 shares valued at about $76.3 million. Meanwhile, Root Financial Partners grew its position by 5,115 shares, ending with 12,318 shares worth about $3.2 million. Pictet North America Advisors took a new position by purchasing 2,747 shares worth about $718,588.
AbbVie Inc. Stock Down 0.2%
AbbVie shares closed at $284.80 on October 21, 2026, and recently traded around that same level. The stock sits below its 52-week high of $291.40 and well above its 52-week low of $190.75. Shares are trading about 8.5% above their 50-day moving average of $262.45 and roughly 21.7% above their 200-day moving average of $233.95.
Recent Earnings
AbbVie reported $64.4 billion in trailing twelve-month revenue along with a net profit margin of 9.8% and earnings of $3.54 per share. Investors look ahead to the company's next earnings report, scheduled for October 30, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
4 analysts raised price targets.
-
EPS & revenue
EPS met estimates. Revenue met estimates.
-
Profit surprise
EBITDA missed by 42 percent. Operating income missed by 72 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
4 target raises.
-
Earnings quality
Gross margin up 1.9 points. Operating margin up 3.6 points. Positive free cash flow.
Earnings Call Summary
AbbVie delivered strong first quarter results with $15 billion in sales and earnings per share of $2.65, beating expectations. Skyrizi sales hit $4.5 billion with 29 percent growth in psoriasis and inflammatory bowel disease markets. Rinvoq brought in $2.1 billion with 20 percent growth across rheumatology and gastroenterology, and the company is preparing to launch the drug in alopecia areata and vitiligo later this year.
Guidance The company raised full year earnings per share guidance to between $14.08 and $14.28, up $0.12. They now expect about $67.3 billion in total sales for the year. They also raised guidance for second quarter to about $16.7 billion in revenue and earnings per share between $3.74 and $3.78.
Fine but not compelling. Acceptable results that likely do not create a meaningful forward reset.
Dividend
The company pays an annual dividend rate of $6.92 per share, yielding 2.45% with a payout ratio of 190.4%.
Insider Buying and Selling at AbbVie Inc.
Company insiders executed several transactions earlier in the year. General Counsel Perry C. Siatis sold 22,381 shares on February 25, 2026, at a price of $230.00 for a total value of $5.1 million. Siatis later sold 18,668 shares on March 2, 2026, valued at $4.4 million. Officer David Ryan Purdue sold 5,230 shares on March 4, 2026, at $233.56 per share for a total of $1.2 million. Officer Nicholas Donoghoe sold 32,710 shares on August 14, 2026, at $250.00 per share, totaling $8.2 million.
Analysts Set New Price Targets
Wall Street analysts have updated their views on the stock ahead of upcoming results. JP Morgan maintained an Overweight rating on October 8, 2026, and raised its price target from $285.00 to $300.00. UBS kept a Neutral rating on October 9, 2026, lifting its target from $260.00 to $275.00. Guggenheim reiterated a Buy rating with a $288.00 target on October 9, 2026. RBC Capital reiterated an Outperform rating with a $280.00 target on October 13, 2026. Barclays maintained an Overweight rating on October 21, 2026, and raised its price target from $300.00 to $325.00. Across the broader analyst community, the stock holds a consensus buy rating and an average price target of $282.61.
About AbbVie
AbbVie is a research-based biopharmaceutical company that develops and markets medicines across immunology, oncology, and neuroscience. Its key products include autoimmune treatments Skyrizi and Rinvoq, along with cancer therapies like Imbruvica, Venclexta, and Elahere. Institutional shifts in companies like AbbVie reflect ongoing portfolio adjustments by large asset managers as new clinical and financial data emerges.
Bottom Line
Vest Financial's trimmed stake highlights how institutional portfolios evolve around major pharmaceutical firms. Investors will watch the upcoming earnings release on October 30, 2026, for fresh insights into revenue trends and product sales.
Related Filing Alerts
Source: Vest Financial's 13F filing on $ABBV (Oct 21, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts